

WFS1 T699M — Wolframin

Threonine → Methionine at position 699 in lumenal domain. ClinVar Conflicting including monogenic hearing loss. AlphaMissense 0.603, $\Delta\Delta G$ +0.01 (neutral). Same position as T699P (Atlas card).

IDENTITY

Variant	T699M (p.Threonine699Methionine)
DNA change	c.2096C>T
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV000004522
Amino acid change	Threonine (T) → Methionine (M) — small polar hydroxyl replaced by flexible sulfur-containing hydrophobic.

STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 699	89.00 HIGH CONFIDENCE
Domain	C-terminal lumenal domain (653-869)
Position context	C-terminal lumenal domain · position 699 (pLDDT 89). Same as T699P.
IDR flag	No — pLDDT well above 50 threshold

Position 699 same neighbors as T699P: TRP700 (2.4 Å — Cat 2 outlier W700S region), VAL698 (2.5 Å), PHE825 (3.4 Å — W700-F825 π -stacking partner), SER826 (4.3 Å). T699M is the second pathogenic substitution at 699 (with T699P). Where T699P introduced a backbone kink, T699M conservatively swaps small polar for small hydrophobic. Both perturb the W700-F825 π -stacking geometry that pulls W700S into Cat 2 destabilization. $\Delta\Delta G$ neutral; AM 0.603 + monogenic hearing loss confirm severe consequence.

COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE 0.603	DYNAMUT2 $\Delta\Delta G$ 0.01 kcal/mol	PLDDT (ALPHAFOLD) 89.00
-------------------------------	---	-----------------------------------

am_class: **LPath** —
threshold > 0.564

Stabilising · Job
177992467372

high confidence

CLINICAL EVIDENCE

ClinVar classification

CONFLICTING CLASSIFICATIONS OF PATHOGENICITY

Review status

criteria provided, conflicting classifications

Last evaluated

2025/09/10 00:00

Inheritance

Monogenic hearing loss.

WFS1 variant landscape

T699M is 1 of ~326 pathogenic-spectrum
variants in WFS1 (out of 2,243 in ClinVar)

- Monogenic hearing loss

RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$ + binding site affected → CATEGORY 3 – docking experiments $\Delta\Delta G$
2–4 → CATEGORY 2 – pharmacological chaperones $\Delta\Delta G > 4$ → CATEGORY 1 –
gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable
fold + functional site hit → CATEGORY 4 – site-specific docking

Category 4 — Stable Fold, Function Disrupted. $\Delta\Delta G \approx 0$. AlphaMissense
0.603 confirms severe consequence.

Mechanism: W700-F825 π -stacking perturbation via T699 contact.

Therapeutic: same W700-F825 microregion as T699P, W700C, W700S.

T699M + T699P + W700C + W700S — four Atlas variants converge on the
W700-F825 π -stacking interface.